Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Molecular Dynamics MegaBACE 1000 DNA sequencer sales ramp-up depends on initial market acceptance.

This article was originally published in The Gray Sheet

Executive Summary

MOLECULAR DYNAMICS MEGABACE 1000 DNA SEQUENCER FULL-SCALE LAUNCH is contingent on the level of market acceptance in the second phase of the company's three-stage roll-out strategy, the company says. "During the latter part of 1998, we will go into the broader market launch of this product, but that will depend on the level of demand we experience in" the ongoing phase-two marketing, President and CEO Jay Flatley told investors at a Jan. 12 session of the Hambrecht & Quist health care conference in San Francisco.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT009481

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel